Active Studies
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies
To conduct a Phase 2 clinical trial of CT1812, a novel disease-modifying compound, in patients with mild to moderate dementia with Lewy bodies (DLB)